New treatment approach for triple negative breast cancer using innovative drug delivery
Development of CA-IL-12 for Triple Negative Breast Cancer
This study is testing a new way to deliver cancer-fighting drugs directly to triple negative breast cancer tumors, which could help make treatments more effective and reduce side effects for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cytonus Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10917204 on NIH RePORTER |
What this research studies
This research focuses on developing a novel drug delivery system called CargocytesTM, which is designed to effectively target and treat triple negative breast cancer by delivering therapeutic agents directly to the tumor microenvironment. The approach aims to minimize side effects by ensuring that the drugs are concentrated where they are needed most, rather than affecting healthy tissues. CargocytesTM are engineered to have unique properties that allow them to navigate through the body and penetrate tumor tissues more effectively than traditional methods. This innovative platform could potentially enhance the efficacy of cancer treatments for patients with metastatic disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those with metastatic disease.
Not a fit: Patients with non-breast cancers or those whose cancer is not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for triple negative breast cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in using targeted drug delivery systems for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Columbus, United States
- Cytonus Therapeutics, INC. — Columbus, United States (Active)
Researchers
- Principal investigator: Filardo, Edward J — Cytonus Therapeutics, INC.
- Study coordinator: Filardo, Edward J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.